Mylan Pharmaceuticals, Inc. v. Thompson
United States Court of Appeals for the Federal Circuit
268 F.3d 1323 (2001)
Relevant factsFree
The casebook excerpt does not provide the underlying facts of this case, focusing instead on the statutory framework governing Abbreviated New Drug Applications (ANDAs) under the Hatch-Waxman Act.
IssueFree
Whether a generic drug manufacturer commits patent infringement by filing an Abbreviated New Drug Application for purposes of marketing a product claimed in the patent prior to the expiration of the patent.
Related cases
AcroMed Corp. v. Sofamor Danek Group Inc.253 F.3d 1371 (2001)Amazon.com, Inc. v. Barnesandnoble.com, Inc.239 F.3d. 1343 (2001)New York Time Company, Inc. v. Tasini533 U.S. 483 (2001)Cable News Network L.P. v. CNNews.com162 F. Supp. 2d 484 (2001)Nelson-Salabes, Inc. v. Morningside Holdings2001 WL 419002 (2001)